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Introduction {#sec1}
============

The RNA interference (RNAi) machinery acts as the major antiviral mechanism in insects ([@bib15], [@bib29], [@bib61]). Dicer-2 (Dcr-2) detects viral dsRNA, from replication intermediates or RNA secondary structures, and processes it to produce 21 nt-long small-interfering RNAs (siRNAs) that are subsequently loaded into a RNA-induced silencing complex (RISC). As part of the RISC complex, the Argonaute-2 (Ago2) endonuclease degrades cognate viral RNA in a sequence-specific manner ([@bib31]). Recent studies ([@bib16], [@bib17]) revealed a pathway for amplification of the virus-specific siRNA response in which viral RNA is reverse transcribed to viral DNA (vDNA) by cellular reverse transcriptase (RT) from long-terminal repeat (LTR) retrotransposons. Transcripts generated from vDNA feed into the RNAi machinery, resulting in more abundant and diverse siRNAs. Chemical inhibition of vDNA production by azidothymidine (AZT) treatment, in either *Drosophila* infected with flock house virus (FHV) or mosquitoes infected with chikungunya virus, leads to loss of virus persistence and death of infected animals ([@bib16], [@bib17]). In addition, siRNAs transcribed from vDNA were shown to shuttle to uninfected cells via exosome transport and confer protection against infection ([@bib58]). Thus, synthesis of vDNA is a component of the antiviral immune response in insects, pivotal to establishing persistent virus infections.

Although vDNA was shown to play a key role in antiviral immunity in insects, questions remain regarding the nature, biogenesis, and regulation of vDNA. The molecular events mediating initiation and extension of reverse transcription are well characterized for retroviruses and retrotransposons ([@bib20]); however, there is scant information on how viral RNA and retrotransposon RT interact to generate vDNA. The identification of retrotransposon-vDNA chimeras supports a model wherein vDNA arises through a copy-choice mechanism of recombination ([@bib16]), which would require co-localization of viral RNA, RT, and retrotransposon RNA. Where this might occur is not apparent. During retrotransposition, reverse transcription occurs in the cytoplasm in virus-like particles (VLP) ([@bib4]); thus viral RNA may be packaged into VLPs. In contrast, RNA virus replication occurs in membrane-associated replication complexes ([@bib14], [@bib18], [@bib37]), and RT may localize to sites enriched in viral RNA/dsRNA. If so, a signaling mechanism activated during virus infection may re-direct the RT complex toward replication sites or to the antiviral RNAi complex.

During RNA virus infection of mammals, pathogen-associated molecular patterns (PAMPs) are detected by cellular sensors named pattern recognition receptors (PRRs), which trigger type I interferon and other immune responses ([@bib39]). One type of PRR, the cytoplasmic RIG-I-like receptors (RLRs), carries a DExD/H-box helicase domain that is phylogenetically related to the N-terminal DExD/H-box helicase domain of *Drosophila* Dcr-2 ([@bib12], [@bib42]). Indeed, RLRs and *Drosophila* Dcr-2 are grouped into the duplex RNA-activated ATPases (DRAs) family ([@bib33]). DRAs bind dsRNA and ATP, resulting in conformational changes that expose signaling domains and binding sites for partner proteins ([@bib33]). The cytoplasmic RLRs preferentially bind short RNAs and defective viral genomes (DVGs), which comprise truncated or rearranged viral genomes and viral genomes carrying sequences of non-viral origin ([@bib3], [@bib49], [@bib35], [@bib55]). DVGs are a byproduct of copy-choice recombination during viral replication, resulting from the high, yet relaxed, processivity of the viral RNA polymerase ([@bib26], [@bib51]). A sub-category of DVGs, referred to as defective interfering (DI) genomes, can inhibit productive virus replication by hijacking factors required for replication and packaging ([@bib35]). DVGs are produced by all arboviruses and can be transmitted between invertebrate and vertebrate hosts, as exemplified by the long-term transmission of a dengue virus DVG ([@bib1]). In mammals, DVGs are known PAMPs that activate type I interferon through MAVS and participate in dendritic cell maturation ([@bib65], [@bib66]). In *Drosophila*, DVGs are preferentially targeted by the RNAi machinery, suggesting a link between defective genomes and viral persistence ([@bib21], [@bib22], [@bib62]). The structural and functional similarities among RLRs, which sense DVGs in mammals, and other DRA family proteins raise the question of whether Dcr-2 plays a similar role in insects.

In this work, we dissect the nature, biogenesis, and mechanism of vDNA synthesis. We demonstrate that vDNA produced during infection of fruit flies and mosquitoes is present in both linear and circular form. The presence of circular viral DNA (cvDNA) per se is sufficient to produce siRNAs that confer partially protective immunity when challenged with a cognate virus. The sequences of cvDNAs bore homology to DVGs. We show that DVGs are a major template for vDNA and cvDNA synthesis in infected fruit flies and that they act as PAMPs in amplification of the vDNA-mediated antiviral RNAi response. Furthermore, we show that vDNA synthesis is regulated by the DExD/H helicase domain of Dcr-2 in a mechanism distinct from the generation of siRNAs. Together, these results suggest that Dcr-2 functions similar to a PRR, together with DVGs acting as PAMPs, to modulates the antiviral immune response in insects. Our work reveals a convergence between invertebrate antiviral immunity and the mammalian type I interferon response and suggests strategies to curtail arbovirus infections in insects by optimizing the protective response provided by circular viral DNAs.

Results {#sec2}
=======

Circular vDNA Produced during RNA Virus Infection of Insects Confers Virus-Specific Immunity {#sec2.1}
--------------------------------------------------------------------------------------------

Elucidating mechanisms important in the biogenesis of vDNA may be gleaned from sequence analysis of vDNAs. The vDNA generated during FHV infection of *Drosophila* S2 cells and fruit flies is linked to LTR-retrotransposon sequences ([@bib16]). Since most retrotransposons generate unintegrated circular DNA ([@bib4]), we hypothesized that both circular and linear forms of vDNA would be present at early times after infection. Wild-type fruit flies were mock-infected or infected with FHV, *Drosophila* C virus (DCV), or Sindbis virus (Sindbis) and collected 7 (FHV and DCV) and 4 (Sindbis) days post-infection. A portion of total DNA was extracted and treated with DNase Plasmid-Safe, an ATP-dependent DNase that removes linear DNA. After treatment, DNA was analyzed by PCR using primers for viruses, mitochondrial DNA, and the Rp49 gene. Both mitochondrial (mtDNA) and Rp49 DNA were amplified in absence of DNase-PS ([Figures 1](#fig1){ref-type="fig"}A--1C). However, mtDNA, but not Rp49 DNA, was amplified in samples treated with DNase-PS, confirming that linear DNA was selectively removed by DNase-PS treatment ([Figures 1](#fig1){ref-type="fig"}A--1C). vDNA was present in both non-treated and DNase-PS-treated samples from FHV, DCV, and Sindbis-infected flies, but not in mock-infected flies (Tris). The amplification of viral sequences in DNase-PS-treated samples was confirmed by sequencing PCR products. Thus, both linear and circular viral DNA (cvDNA) were produced during infection in flies ([Figures 1](#fig1){ref-type="fig"}A--1C). Furthermore, cvDNA was detected as early as 16 hr after FHV infection ([Figure S1](#mmc1){ref-type="supplementary-material"}A, related to [Figure 1](#fig1){ref-type="fig"}) and 24 hr after DCV infection ([Figure S1](#mmc1){ref-type="supplementary-material"}B, related to [Figure 1](#fig1){ref-type="fig"}) in S2 *Drosophila* cells. Finally, we infected mosquitoes with chikungunya virus (CHIKV) and detected both linear and circular forms of CHIKV vDNA ([Figure 1](#fig1){ref-type="fig"}D). The presence of cvDNA in two different insects using four different viruses indicates that cvDNA is a common feature of the vDNA synthesis pathway during the antiviral immune response.Figure 1Circular vDNA Produced during RNA Virus Infection of Insects Confers Virus-Specific Protective Immunity(A) Wild-type flies were infected with FHV or mock infected (Tris). DNA was extracted from individual flies and RNase treated, and linear DNA was digested with Plasmid-Safe DNase (DNase-PS). Amplification of Rp49 by PCR shows linear DNA, while amplification of mitochondrial DNA (mtDNA) is a control for circular DNA. Linear and circular DNA from FHV RNA1 and RNA2, the two FHV genomic segments, is detected by PCR.(B) Flies were injected with DCV and processed as in (A).(C) Flies were injected with Sindbis virus and processed as in (A).(D) Mosquitoes were fed chikungunya virus (CHIKV) through a blood meal and processed as in (A). CHIKV circular vDNA presence was assessed by PCR, and actin was used as a control for linear DNA.(E) Wild-type flies were infected with Sindbis replicon, and linear and circular forms of vDNA were detected as described in (A).(F) Wild-type flies were immunized with 10 ng of circular vDNA isolated from FHV-infected S2 cells (cvDNA FHV), mitochondrial DNA isolated from uninfected S2 cells (mtDNA), or mock infected (Tris). Three days later, flies were challenged with 80 TCID~50~ FHV or with Tris. "cvDNA FHV-FHV" indicates flies immunized with FHV cvDNA and challenged with FHV.(G) Wild-type flies were immunized as described in (F) and challenged with 100 TCID~50~ DCV or with 80 TCID~50~ FHV. Survival was monitored daily. Molecular weights (MW) are indicated.(A--G) Data are representative of three independent experiments. (F and G) Dots represent mean and SEM (n = 75 flies per condition). ns, not significant; ^∗∗∗∗^p \< 0.0001 (log-rank test). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Since circular DNA is more stable than linear DNA, we examined the stability of vDNA produced in insect cells. For these experiments, we used a Sindbis replicon ([@bib5]), which undergoes only a single replication cycle. Thus, any vDNA detected after infection was synthesized from this single cycle, allowing us to follow the fate of cvDNA molecules. Wild-type flies were infected with 1,000 particles of Sindbis-replicon and collected at various times post-inoculation ([Figure 1](#fig1){ref-type="fig"}E). cvDNA appeared as early as 24 hr post-infection and was maintained up to 2 weeks post-infection, indicating that cvDNA is an abundant and long-lasting form of vDNA.

The presence and persistence of cvDNA during infection in insects suggest that these circular forms are biologically relevant. Previous studies found that vDNA participates in the antiviral response ([@bib16], [@bib17], [@bib58]), and we hypothesized that cvDNA may be sufficient to induce a protective, virus-specific immune response in naive flies. To test this, cvDNA (free of viral RNA) was isolated from FHV-infected *Drosophila* S2 cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C, related to [Figure 1](#fig1){ref-type="fig"}). Flies injected with this cvDNA were challenged with homologous FHV 2 days later. We observed a significant increase in survival time in flies immunized with cvDNA from FHV-infected cells, but not circular DNA from uninfected cells ([Figure 1](#fig1){ref-type="fig"}F). This effect was sequence specific, as flies immunized with FHV cvDNA and challenged with DCV were not protected ([Figure 1](#fig1){ref-type="fig"}G). This increased survival was not accompanied by a similar decrease in virus titer (data not shown), as previously observed in mosquitoes ([@bib17]). Together, these results demonstrate that a portion of vDNA produced during infection is circular, that the circular form is long lasting, and that cvDNA alone can induce a virus-specific immune response against homologous virus challenge.

Circular vDNA Protection Is Mediated by the siRNA Response {#sec2.2}
----------------------------------------------------------

It is currently thought that vDNA amplifies the immune response by boosting production of siRNAs ([@bib16], [@bib17], [@bib58]). To determine if cvDNA induces virus-specific siRNAs, we inoculated flies with cvDNA from FHV- and mock-infected S2 cells, and after 3 days small RNAs were purified and deep sequenced. We detected FHV RNA1- and RNA2-specific siRNAs of positive and negative polarity in flies injected with cvDNA from FHV-infected cells ([Figures 2](#fig2){ref-type="fig"}A and 2B), while no FHV-siRNAs were detected in flies injected with cvDNA from uninfected cells (data not shown). The siRNAs mapped across the FHV genome ([Figures 2](#fig2){ref-type="fig"}C and 2D), suggesting that cvDNAs comprise a large number of different viral sequences and/or full-length viral sequences. These data, together with results from the previous section, indicate that cvDNA induce a protective siRNA antiviral response against homologous virus infection.Figure 2Circular vDNA Protection Is Mediated by the siRNA Response(A and B) Circular vDNA isolated from FHV-infected S2 cells was injected into naive wild-type flies. siRNAs were deep sequenced at 3 days post-inoculation and mapped on FHV RNA1 and RNA2, respectively. Graph shows size distribution of small RNAs mapping on FHV genome.(C and D) siRNA coverage from circular vDNA on FHV RNA1 and RNA2. Uncovered regions are represented as gray lines.Data are representative of three independent experiments.

Circular vDNAs Are Chimeras of Viral and LTR-Retrotransposon Sequences {#sec2.3}
----------------------------------------------------------------------

Previous studies indicate that vDNA is largely comprised of truncated genomes and/or chimeric genomes containing LTR-retrotransposon sequences and viral sequences ([@bib16]), and cvDNAs likely comprise a similar heterogeneous population of chimeric, partial, and truncated viral genomes. To characterize this heterogeneous population, we initially cloned and sequenced individual cvDNA molecules. Although both FHV RNA1 and RNA2 produce cvDNA ([Figure 1](#fig1){ref-type="fig"}A), our cloning strategy focused on RNA1. Four chimeric cvDNA structures that share common features are shown in [Figure 3](#fig3){ref-type="fig"}. Each contains chimeric genotypes formed from discontinuous, sub-genomic regions of FHV RNA1 circular DNA and sequences from *Drosophila* retrotransposons. Each of the cvDNAs shared a similar recombination junction around nucleotides 311/957 in FHV RNA1, while two of the four had a second recombination junction around 1,200/2,280 ([Figures 3](#fig3){ref-type="fig"}C and 3D). Interestingly, the FHV RNA1 sequences were found in opposite orientation with respect to retrotransposon sequences. This indicates that minus sense viral RNA can also serve as templates for copy-choice recombination during reverse transcription, and rules out a mechanism of vDNA biogenesis whereby viral genomic RNA is co-packaged into retrotransposon VLPs. We tested if our panel of cvDNAs could induce a siRNA response in cells or flies. However, neither FHV-specific transcripts nor siRNAs were detected in naive S2 cells transfected with cvDNA plasmids or in flies inoculated with excised, religated, plasmid-free cvDNAs (data not shown). The lack of response may reflect limitations in the quantity, quality, and/or diversity of cvDNA sequences in the transfected cells and inoculated flies.Figure 3Circular vDNAs Are Chimeras of Viral and LTR-Retrotransposon Sequences(A--D) Individual cvDNA isolated from FHV-infected S2 cells was cloned and sequenced. Numbers below indicate the nucleotide position in the FHV RNA1 sequence (gray) or in the retrotransposon sequence (blue, with their names). Recombination junctions in FHV are indicated by a vertical orange line. Recombination junctions where at least a 3 nt overlap was present are indicated by asterisks. Arrows indicate the orientation of the sequence with respect to FHV or retrotransposon.

For more comprehensive genetic characterization of cvDNAs, we undertook an unbiased deep sequencing analysis of circular DNA from FHV-infected and uninfected cells, using a strategy designed to enrich extrachromosomal circular DNA ([@bib24]). No reads corresponding to FHV sequences were found in uninfected cells (data not shown). In FHV-infected cells, 8,203 reads had total or partial sequences corresponding to FHV RNA1 and RNA2 ([Figure 4](#fig4){ref-type="fig"}A). Of these, 4,023 reads comprised non-continuous FHV sequences, the majority (3,790) containing two non-continuous regions of the FHV genome. The remaining 233 reads were chimeras that matched both FHV and *Drosophila melanogaster* genomes. As *Drosophila* reads in chimeric vDNAs comprise mainly transposon sequences ([@bib16]), we mapped the 233 FHV-*Drosophila* chimeric reads against the transposon database available at Flybase. Fifteen retrotransposons were present in the 133 reads that matched to the transponson database, with *Diver* accounting for 44% of matches ([Table S1](#mmc1){ref-type="supplementary-material"}, related to [Figure 4](#fig4){ref-type="fig"}). The chimeric FHV-retrotransposon reads on *Diver* mapped primarily to the LTRs, with some reads mapping to the coding region of the retrotransposon ([Figure 4](#fig4){ref-type="fig"}B), suggesting a mechanism for LTR-driven transcription of cvDNA ([@bib4]).Figure 4Circular vDNAs Are Chimeras of LTR-Retrotransposons and Viral Sequences Enriched in DVG Sequences(A) Table presenting the type of reads obtained by deep-sequencing of FHV cvDNAs isolated from infected S2 cells. See also [Table S1](#mmc1){ref-type="supplementary-material"}.(B) Graph shows distribution of reads and coverage for the LTR and the coding sequence of the retrotransposon *Diver* for the reads "FHV--transposon chimeric read" of (A).(C and D) Read coverage of cvDNA isolated from FHV-infected S2 cells is represented for FHV RNA1 (C) and RNA2 (D). Reads were mapped with the local (red) or end-to-end method (black).

The distribution of individual reads along the FHV RNA1 and RNA2 genome was done using both end-to-end and local mapping tools ([Figures 4](#fig4){ref-type="fig"}C and 4D). Although reads covered the entirety of RNA1 and RNA2, cvDNA sequences were not uniformly distributed along the FHV genome. This was especially true for RNA1, where there were more reads in the regions between nucleotides 190--300, nucleotides 640--740, and nucleotides 1,060--1,230 ([Figure 4](#fig4){ref-type="fig"}C). The skewed distribution was most evident when using the local mapping method, which does not require both ends of the read to match the target genome. This suggests that the non-uniform distribution of FHV sequences in cvDNA is associated with the presence of large quantities of non-continuous viral genomes. To support this, we noted that the regions of RNA1 that were over-represented matched the sequences detected in our four cvDNA clones, where we could identify specific junctions between non-continuous portions of FHV RNA1 ([Figure 3](#fig3){ref-type="fig"}). Notably, most of the FHV RNA1 sequences over-represented in cvDNA corresponded to sequences of previously described FHV DVGs ([@bib21], [@bib22]), raising the possibility that DVGs might be the preferred templates for the cvDNA synthesis.

Defective Genomes Are Templates for vDNA Synthesis and Enhance Antiviral Immunity {#sec2.4}
---------------------------------------------------------------------------------

To explore the hypothesis that DVGs might be templates for vDNA synthesis, we used Sindbis virus, for which we demonstrated that infected flies produced both vDNA and cvDNA ([Figure 1](#fig1){ref-type="fig"}C). In addition, through reverse genetics we are able to extrinsically adjust and intrinsically modify the presence of DVGs ([@bib45]). Flies were inoculated either with wild-type virus (Sindbis-WT) or with Sindbis-WT supplemented with a previously characterized Sindbis DVG, designated D~G~ ([@bib45]). At 7 hr post-infection, total DNA was extracted from individual flies and amplified by PCR using primers specific for Sindbis virus or Sindbis D~G~. Sindbis vDNA was amplified from both groups of flies ([Figure 5](#fig5){ref-type="fig"}A), while D~G~ sequences were detected only in flies infected with Sindbis-WT + D~G~ ([Figure 5](#fig5){ref-type="fig"}A, lanes 9 and 12), indicating that DVG is a template for vDNA synthesis. To determine if DVGs are also a template for cvDNA synthesis, DNA from infected flies was treated with DNase-PS and amplified using Sindbis or D~G~-specific primers. cvDNA was detected in both groups of flies ([Figure 5](#fig5){ref-type="fig"}B): cvDNA corresponding to D~G~ sequences was detected in Sindbis WT+D~G~-infected flies ([Figure 5](#fig5){ref-type="fig"}B, lanes 8 and 11), and other cvDNA forms amplified by Sindbis primers were detectable ([Figure 5](#fig5){ref-type="fig"}B, lanes 2, 4, 5, 8, and 12). Thus, DVGs can serve as templates for both linear and circular forms of vDNA.Figure 5Defective Viral Genomes Are a Preferential Template for Circular vDNA Synthesis and Regulate Viral Load(A) Wild-type flies were injected with Sindbis-WT or Sindbis-WT+D~G~ and collected at 7 hr post-infection. Presence of D~G~ vDNA as well as Sindbis vDNA was assessed in individual flies by PCR. Fly DNA was detected by PCR targeting Rp49, and Sindbis RNA was detected by RT-PCR.(B) Individual flies were injected with Sindbis-WT or Sindbis-WT+D~G~, and DNA was extracted and treated with DNase-PS to isolate circular DNA. cvDNA from Sindbis was amplified in both conditions, while D~G~ cvDNA was only amplified in Sindbis-WT+D~G~-injected flies.(C) Wild-type flies were injected with Sindbis-WT or Sindbis-highDG and titered individually after infection (0 days post-infection, n = 3 flies) or at 3, 5, and 7 days post-infection (n = 10 flies per condition).(D) *Ago2*^--/--^ flies were infected as described in (C).(E) Wild-type flies were fed with AZT or control solution, then infected with Sindbis-WT or Sindbis-highDG and titered 3 days post-infection. Control: Sindbis-WT, n = 32 flies; Sindbis-highDG, n = 31. AZT: Sindbis-WT, n = 25; Sindbis-highDG, n = 27.(F) *Aedes aegypti* mosquitoes were fed blood meals containing the indicated chikungunya stocks. P3 and P5 indicate number of passages. Low and high indicate passages at low and high MOI, respectively. Mosquitoes (n = 30 per condition) were collected 12 days post-infection, and presence of virus was assessed by plaque assay.(G) Mosquitoes were fed for a week prior to infection with sucrose supplemented or not with 5 mM AZT, then infected with CHIKV StartingStock, P5-low or P5-high and processed as in (F).Molecular weights (MW) are indicated. Data are representative of three (A--F) or two (G) independent experiments. Bars show mean. ns, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001 (two-way ANOVA \[C and D\], Mann-Whitney test \[E\], or Chi-square test \[F and G\]). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We next asked whether vDNA synthesized from DVGs can amplify a siRNA-dependent antiviral response *in vivo*, similar to what was observed for vDNA from FHV. Flies were inoculated with Sindbis-WT or with a Sindbis mutant that produces high levels of DVGs (designated Sindbis-highDG). This mutant bears a point mutation in the viral polymerase that leads to higher mutation and recombination rates, and overproduction of DVGs in cell culture (noted as SINV-G in [@bib45]) and *in vivo* ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B, related to [Figure 5](#fig5){ref-type="fig"} and [STAR Methods](#sec4){ref-type="sec"}). We infected wild-type and *Ago2*^--/--^ flies with Sindbis-WT or Sindbis-highDG and measured viral titers at sequential times post-infection. In wild-type flies, there was a 4- to 5-fold decrease in virus titer throughout infection with Sindbis-highDG as compared to Sindbis-WT ([Figure 5](#fig5){ref-type="fig"}C). However, a similar decrease in virus titer was not observed in *Ago2*^--/--^ flies ([Figure 5](#fig5){ref-type="fig"}D), demonstrating that the enhanced antiviral response to Sindbis-highDG was RNAi dependent. As a control, we used a third virus, Sindbis-equalDG, which has the same mutation rate as Sindbis-highDG ([@bib54]) but produces DVGs at wild-type levels ([Figure S2](#mmc1){ref-type="supplementary-material"}B, related to [Figure 5](#fig5){ref-type="fig"}). Sindbis-equalDG showed similar titers as Sindbis-WT in both wild-type and *Ago2*^--/--^ flies ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D, related to [Figure 5](#fig5){ref-type="fig"}). This result confirms that overproduction of DVGs triggers the RNAi-dependent decrease in viral load.

Previous studies show that both the Jak-Stat and IMD pathways mediate the Sindbis antiviral response in *Drosophila* ([@bib2], [@bib13]). To confirm that the DVG-enhanced antiviral response was specifically RNAi mediated, *hopscotch*^−/−^ and *Rel*^−/−^ mutant flies, which contain mutations in the Jak-stat and Imd pathways, were inoculated with Sindbis-WT or Sindbis-highDG. Similar to wild-type flies, virus titers were reduced in Jak-Stat and IMD mutants infected with Sindbis-highDG as compared to Sindbis-WT infection ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F, related to [Figure 5](#fig5){ref-type="fig"}). Together with the results in *Ago2*^--/--^ flies ([Figure 5](#fig5){ref-type="fig"}D), these data establish that the DVG-enhanced antiviral response depends specifically on an intact RNAi response.

Since DVGs can template for vDNA and cvDNA, and since overproduction of DVGs leads to decreased virus titers in a RNAi-dependent manner, we asked whether DVG-enhanced antiviral response is mediated by vDNA. Flies were fed AZT, a drug that inhibits reverse transcription and synthesis of vDNA ([@bib16], [@bib17], [@bib58]), and infected with Sindbis-WT or Sindbis-highDG. Treatment of flies with AZT had no effect on virus titers in Sindbis-WT infected flies but largely rescued the drop in titer seen in Sindbis-highDG-infected flies ([Figure 5](#fig5){ref-type="fig"}E). This result establishes that the enhanced antiviral response requires production of vDNA and cvDNA from DVGs.

Finally, we tested whether the production of DVGs also modulates the outcome of infection in mosquitoes. Increased proportions of DVGs are produced when RNA virus stocks are passaged at high multiplicity of infection (MOI) ([@bib19], [@bib45]). To generate CHIKV stocks enriched in DVGs, a starting stock was passaged three and five times at low or high MOI to generate stocks with low and high DVG content, respectively. *Aedes aegypti* mosquitoes were then inoculated with these stocks via blood feeding, and the presence of infection was determined in whole mosquitoes after 12 days. The infection rate decreased in mosquitoes fed high MOI/high DVG virus stocks, compared to low MOI/low DVG virus stocks ([Figure 5](#fig5){ref-type="fig"}F, P3-high and P5-high compared to P3-low and P5-low). To verify that reduced infectivity was related to vDNA production, mosquitoes were fed AZT a week prior to infection. AZT treatment rescued the decreased infection rate of the P5-high stock ([Figure 5](#fig5){ref-type="fig"}G). Together, these experiments demonstrate that high levels of DVGs can enhance antiviral immunity in insects via an RNAi-dependent mechanism that is mediated through vDNA production.

The Helicase Domain of Dcr-2 Regulates the Production of vDNA from Defective Viral Genomes {#sec2.5}
------------------------------------------------------------------------------------------

DVGs are potent stimulators of innate immunity in mammals, acting through RLRs ([@bib55], [@bib57]). As the RLRs and Dcr-2 are both members of the DRA family of RNA-dependent ATPases, we hypothesized that the helicase of Dcr-2 in fruit flies may play an important role in the synthesis of vDNA from DVGs, perhaps through RNA binding, sensing, or activation or through recruitment of partner proteins necessary for vDNA biosynthesis. To address this question, we quantified vDNA levels and virus titers in a panel of *Drosophila* Dcr-2 mutants that bear mutations within and outside the helicase domain ([Figure 6](#fig6){ref-type="fig"}A) ([@bib27]). We plotted relative vDNA accumulation (measured by qPCR, [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C, related to [Figure 6](#fig6){ref-type="fig"}) versus relative viral loads (measured by plaque assay) for mutant and wild-type flies infected with Sindbis-WT or Sindbis-highDG ([Figure 6](#fig6){ref-type="fig"}B and [STAR Methods](#sec4){ref-type="sec"}). Certain mutants, such as *Dcr-2*^G31R^, accumulated more vDNA than wild-type flies, whereas other mutants, such as *Dcr-2*^A500V^, accumulated 2-fold less vDNA. Across the panel, we found an inverse correlation between levels of vDNA and relative viral load ([Figure 6](#fig6){ref-type="fig"}B), indicating that Dcr-2 helicase plays a role in both the synthesis of vDNA from DVGs as well as concomitant reduction in virus load. Since Dcr-2 plays a role in the canonical antiviral siRNA pathway, we determined if the role of Dcr-2 in vDNA synthesis was independent of siRNA production. Indeed, *Dcr-2*^A500V^ and *Dcr-2*^G31R^ flies infected with Sindbis virus produced abundant siRNAs distributed across the virus genome ([Figures 6](#fig6){ref-type="fig"}C--6F and [S3](#mmc1){ref-type="supplementary-material"}D--S3G, related to [Figure 6](#fig6){ref-type="fig"}). Thus, mutations in Dcr-2 that impact vDNA synthesis have no discernable effect on siRNA production, indicating distinct roles of Dcr-2 in the biosynthesis of vDNA and siRNA production.Figure 6The Helicase Domain of Dicer-2 Regulates the Production of vDNA from Defective Viral Genomes(A) Schematic of Dcr-2 protein. Point mutations of the helicase domain, as well as the L811fX mutation, which introduces a premature stop codon in the protein, are indicated.(B) Point mutants of Dcr-2 helicase were injected with Sindbis-WT or Sindbis-highDG and collected 7 hr post-infection. For each virus, vDNA accumulation was measured by qPCR and compared to wild-type flies (n = 8--10 flies, mean of three independent experiments). The y axis of the graph plots the relative ratio mutant/wild-type flies for vDNA accumulation. The same mutants were infected with Sindbis-WT or Sindbis-highDG, and mean titers were measured 3, 5, and 7 days post-infection (n = 10 flies per time point). The relative percentage of Sindbis-highDG titers compared to Sindbis-WT titers as a mutant/wild-type flies ratio is plotted on the x axis (mean of three independent experiments). The relative viral loads quantify the drop in titer of Sindbis-highDG compared to Sindbis-WT in each of the indicated Dcr-2 mutants, presented as a ratio on the value obtained for wild-type flies. Spearman correlation test, *R* = −1, p = 0.016 (*Dcr-2*^L811fX^ mutant, in blue, is not included in the correlation).(C--F) *Dcr-2*^A500V^ (C and E) or *Dcr-2*^G31R^ (D and F) flies were injected with Sindbis-WT and siRNAs were deep sequenced at 7 days post-infection. Size distribution of reads (C and D) and distribution of 21 nt reads along Sindbis virus genome (E and F) are shown. Uncovered regions are represented as gray lines.(G) *Drosophila* S2 cells were transfected with a plasmid expressing Dcr-2 helicase tagged with a Flag and V5 tag (helicase), the unrelated protein CG4572 tagged in a similar fashion (CG4572), or the empty plasmid (empty). Cells were then infected with Sindbis-WT or Sindbis-highDG. Before (Input) or after immunoprecipitation with Flag or V5 tag (IP), presence of Sindbis RNA was assessed by RT-PCR. PCR controls (Ctrl) are indicated. Molecular weights (MW) are indicated. Data are representative of two (C--G) independent experiments. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

The helicase domain of Dcr-2 triggers the antiviral effector Vago independently of antiviral RNAi ([@bib12]). Therefore, we tested whether Vago was involved in DVG-mediated decrease of viral titers by infecting *Vago*^--/--^ flies with Sindbis-WT or Sindbis-highDG ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B, related to [Figure 6](#fig6){ref-type="fig"}). Similar to wild-type flies, *Vago* mutant flies displayed lower viral titers for Sindbis-highDG compared to Sindbis-WT, indicating that Vago was not involved in vDNA biosynthesis.

To see if the Dcr-2 helicase domain interacts with viral RNAs, the helicase domain was cloned in the pAct plasmid and tagged with either FLAG or V5 epitopes. S2 cells were transfected with these constructs and infected with Sindbis-WT or Sindbis-highDG. Cell lysates were immunoprecipitated with anti-FLAG or anti-V5 antibodies, and Sindbis RNA was detected by RT-PCR. Controls included lysates from cells transfected with empty vector or with a vector expressing an unrelated protein (CG4572). We detected amplification products specific for Sindbis virus in the Sindbis-highDG conditions, irrespectively of the tag ([Figure 6](#fig6){ref-type="fig"}G), indicating that the helicase domain of Dcr-2 interacts with viral RNA, either through direct binding to viral RNA or via interactions mediated through a partner protein.

The Helicase of Dcr-2 Functions to Modulate vDNA Accumulation and Virus Persistence {#sec2.6}
-----------------------------------------------------------------------------------

The results above reveal that the helicase domain of Dcr-2 is critical for producing vDNA. Furthermore, the outcome of infection would depend on both the level of DVGs in the inoculum and the functional integrity of Dcr-2 in infected flies. To test this, we infected *Dcr-2*^G31R^ and *Dcr-2*^A500V^ flies with Sindbis-WT or with Sindbis-highDG and measured survival. Sindbis-highDG-infected *Dcr-2*^G31R^ flies produced more vDNA and survived longer than Sindbis-WT-infected flies ([Figures 7](#fig7){ref-type="fig"}A and 7B). Notably, vDNA accumulation and fly survival were similar between Sindbis-WT and Sindbis-equalDG in *Dcr-2*^G31R^ flies ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B, related to [Figure 7](#fig7){ref-type="fig"}). In contrast, *Dcr-2*^A500V^ flies, which produce low levels of vDNA, showed no difference in vDNA accumulation ([Figure 7](#fig7){ref-type="fig"}C) and died at the same rate with either virus ([Figure 7](#fig7){ref-type="fig"}D). Heterozygotes generated from *Dcr-2*^G31R^ and *Dcr-2*^A500V^ crossed with wild-type flies were used to account for variations due to genetic background. Survival of heterozygotes was similar when infected with Sindbis-WT, Sindbis-highDG or Sindbis-equalDG ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D, related to [Figure 7](#fig7){ref-type="fig"}). The results indicate that viral persistence and fly survival depend on both the Dcr-2-dependent synthesis of vDNA and the quantity of DVGs available to stimulate the vDNA synthesis pathway.Figure 7The Helicase Domain of Dcr-2 Modulates vDNA Accumulation and Virus Persistence(A) *Dcr-2*^G31R^ flies were injected with Sindbis-WT or Sindbis-highDG, and vDNA was measured at 7 hr post-infection by qPCR (n = 20 flies per condition).(B) *Dcr-2*^G31R^ flies were infected with Sindbis-WT, Sindbis-highDG or mock infected (Tris), and survival was monitored daily (n = 60 flies per condition).(C) *Dcr-2*^A500V^ flies were processed as in (A).(D) *Dcr-2*^A500V^ flies were processed as in (B).(A--D) Bars show mean and SEM, and data are representative of three independent experiments. ns, not significant; ^∗^p \< 0.05; ^∗∗∗∗^p \< 0.0001 (Mann-Whitney test \[A and C\] or log-rank test \[B and D\]). See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In this work, we demonstrate that Dcr-2 plays a critical role mediating two distinct pathways of antiviral immunity in insects: the canonical RNAi pathway and the recently described vDNA amplification pathway. Through its helicase domain, Dcr-2 functions analogous to a PRR to modulate reverse transcription of viral genome products, particularly DVGs, into vDNA. In addition, and through its two RNase III domains, Dcr-2 dices dsRNA to produce siRNAs either from viral origin or from transcripts arising from vDNA transcription. Importantly, we show that modulation of vDNA synthesis by Dcr-2 is independent from the dicing activity: mutants of the helicase domain that alter vDNA production still produce wild-type-like levels of siRNAs. This work provides insights into the mechanism of vDNA biogenesis and establishes strong similarities between insect and mammalian antiviral immunity. In both cases, a RLR helicase domain is required to control viral infection. In insects, Dcr-2 recognition of DVGs activates both the canonical antiviral RNAi pathway and the vDNA amplification pathway, which leads to persistent viral infection.

The helicase domain of Dcr-2 is phylogenetically close to mammalian RLRs that preferentially bind DVGs during infection, leading to the production of type I interferon ([@bib55], [@bib57]). In an analogous manner, our data indicate that the helicase of Dcr-2, together with DVGs, regulates production of vDNA/cvDNA and virus persistence. How Dcr-2 acts to regulate the accumulation of vDNA remains unclear. Based on the related structure of RIG-I ([@bib6], [@bib9], [@bib32]), all the studied mutations in Dcr-2 are in close proximity to the ATP binding site of the helicase (data not shown). ATP binding by RIG-I results in a conformational change leading to interferon production ([@bib23]). In *Drosophila*, an ATP-dependent conformational change in the helicase domain of Dcr-2 was recently found to play a key role in coordinating the recognition and processive cleavage of blunt-end dsRNA ([@bib52], [@bib53]). Thus, recognition and/or cleavage of DVG dsRNA by Dcr-2 helicase might also lead to the activation of vDNA synthesis.

This work further establishes a conserved role of DVGs as PAMPs. The preference of DVGs as PAMPs is likely related to their subcellular localization: full-length viral genomes are better hidden from immune sensors (in membranous invaginations for example), while cytoplasmic DVGs are more available for antiviral sensors and effectors. Indeed, DVGs are preferentially targeted by ADARs during infection in mammals and by RNAi in insects ([@bib60], [@bib44], [@bib62], [@bib63]). DVGs of Sendai virus localize diffusely in the cytoplasm of infected cells, while full-length genomes are concentrated in one area ([@bib64]). Because DVGs behave as PAMPs in both insects and mammals, DVGs may be under high selective pressure, which suggests that viruses may have developed specific strategies to regulate their production, as exemplified by the C protein of measles virus or the matrix protein of lymphocytic choriomeningitis virus ([@bib44], [@bib67]). A recent publication ([@bib64]) demonstrated that establishment of persistent infection in mammalian cells by paramyxoviruses correlates with high DVG production and activation of interferon through the MAVS signaling platform. More than a byproduct of viral replication, DVGs seem to be a key viral product that can modulate the host immune response and the fate of infection.

While our studies suggest that the helicase domain of Dcr-2 is critical for biosynthesis of vDNA, the molecular events resulting in reverse transcription of DVGs remain elusive. The finding that cvDNA is in opposite orientation with respect to retrotransposon sequences indicates that minus-strand viral RNA can serve as a template for reverse transcription. This, together with evidence that DVGs are the major template for vDNA synthesis, likely rules out reverse transcription of genomic viral RNA in VLPs. Rather, it is more likely that reverse transcription occurs via the translocation of the RT complex to a site enriched in DVGs, such as the RNAi complex. Because Dcr-2 targets both retrotransposon RNA and viral RNA in the cytoplasm, it is tempting to speculate that Dcr-2 acts as a RLR to signal translocation of the RT.

Although we do not fully understand the mechanisms of vDNA biosynthesis, it is clear that both linear and circular vDNA forms are generated during RNA virus infection. The cvDNA forms were stable and persisted at least 2 weeks after infection, suggesting their importance in vDNA immune response pathway. Inoculation of flies with cvDNA resulted in increased survival, but not a concomitant decrease in virus titer. Virus titers or RNA copies do not always reflect on the fitness cost of virus infection in insects, which are commonly measured by survival, fecundity, fertility, and other more qualitative phenotypic observations. This is especially so in lab colonies, which live under ideal environmental conditions ([@bib34]). Greater insight into mechanisms of viral pathogenesis during persistent infections is needed to understand the relationship between virus titer and persistence and/or healthy carrier versus non-healthy carrier phenotype.

This cvDNA may be the precursor of integration of viral sequences into host genomes. These integrations, referred to as endogenous viral elements, were recently associated with retrotransposons in the mosquito genome ([@bib10], [@bib41], [@bib56]). In addition to their role in antiviral immunity shown here, circular DNA is commonly found in a number of species, including *C. elegans* and *Mus musculus*, and in human cell lines ([@bib8], [@bib50]). Circular DNA has recently garnered growing attention as a key molecule in health and disease and in regulation of cell communication and cell function ([@bib43]).

Finally, our work demonstrates that virus persistence in insects is dependent on the levels of vDNA produced, which can be modulated either through AZT treatment, through increased levels of DVGs, and/or by mutation of Dcr-2 helicase domain. As such, our work opens the possibility that strategies to modulate levels of vDNA may help control arboviral infection in the insect host. Toward that end, additional studies to optimize and more fully examine the mechanism of cvDNA-mediated control of RNA virus infection are ongoing.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-V5InvitrogenR96025Anti-Flag M2 Magnetic BeadsSigma AldrichM8823**Bacterial and Virus Strains**Flock House virusObtained from Annette Schneemann (The Scripps Research Institute)N/ADrosophila C virusObtained from Jean-Luc Imler (University of Strasbourg)Sindbs virus (strain AR339)([@bib36])N/ASindbis-highDG([@bib47])N/ASindbis-equalDG([@bib54])N/Achikungunya virus (06-049)([@bib7])N/A**Chemicals, Peptides, and Recombinant Proteins**Azidothymidine (AZT)Sigma AldrichA2169**Critical Commercial Assays**mMachine mMessage Transcription KitThermo Fisher ScientificAM1340Phusion High FIdelity DNA polymeraseNEBM0530SPlasmid-Safe ATP-dependent DNaseEpicenterE3101KPower SYBR Green Master MixThermo Fisher Scientific4368577TrizolThermo Fisher Scientific15596018Maxima H Minus First Strand cDNA synthesis kitThermo Fisher ScientificK1681Illustra TempliPhi kitGE Healthcare25640010PicoGreenInvitrogenP7589Nextera XT library kitIlluminaFC-131-1024DNA Bioanalyzer chipAgilent Technologies5067-1505Turbo DNA-free kitLife technologieAM1907NEBNext Multiplex Small RNA Library PrepIlluminaE7300S**Deposited Data**SRAPRJNA387403DNA seq of circular DNA from Drosophila S2 cells infected or not with FHVPRJNA387406Small RNAs of Drosophila *w*^*1118*^ flies inoculated or not with FHV or circular-viral-DNA of FHVPRJNA416764RNA seq of Drosophila *Dicer-2*^*L811fX*^ flies infected with Sindbis-WT, Sindbis-highDG or Sindbis-equalDG virusesPRJNA416718Small RNAs of *Drosophila melanogaster* Dicer-2 mutant flies infected with Sindbis-WT virus**Experimental Models: Cell Lines**Drosophila S2 cellsInvitrogenR69007BHK-21 cells \[C13\]Sigma-Aldrich85011433-1VLVero cellsSigma-Aldrich84113001-1VL**Experimental Models: Organisms/Strains***D. melanogaster*. Wildtype: *w\[1118\]*Bloomington Drosophila Stock CenterBDSC: 3605*D. melanogaster*. Ago-2 mutant: *w^∗^ ; Ago-2\[414\]*[@bib40]Kyoto: 109027*D. melanogaster*. Hopscotch mutant: *y\[1\] hop\[m38\]/FM7c*Gift from JL ImlerN/A*D. melanogaster*. Hopscotch mutant: *hop\[mv1\]/xˆx v+ yy+*Gift from JL ImlerN/A*D. melanogaster*. Relish mutant: *w\[1118\] ;; Df(3) E\[20i\] rel*Gift from JL ImlerN/A*D. melanogaster*. Dicer-2 mutant: *y\[d2\] w\[1118\], P{ry^+t7.2^ = ey--FLP.N}2 ; Dcr-2\[L811fX\]*([@bib59])N/A*D. melanogaster*. Dicer-2 helicase mutant: *yw ; Dcr-2\[G31R\]*([@bib27])\
Gift from JL ImlerN/A*D. melanogaster*. Dicer-2 helicase mutant: *yw ; Dcr-2\[G173E\]*([@bib27])\
Gift from JL ImlerN/A*D. melanogaster*. Dicer-2 helicase mutant: *yw ; Dcr-2\[C473Y\]*([@bib27])\
Gift from JL ImlerN/A*D. melanogaster*. Dicer-2 helicase mutant: *yw ; Dcr-2\[A500V\]*([@bib27])\
Gift from JL ImlerN/A*D. melanogaster*. *Vago\[ΔM10\]*:([@bib12])\
Gift from JL ImlerN/A*D. melanogaster*. Vago control strain([@bib12])\
Gift from JL ImlerN/A*Aedes aegypti*. Wildtype collected in Thailand([@bib28])N/A**Oligonucleotides**Sindbis virus 414FEurogentecAAGGATCTCCGGACCGTACTSindbis virus 913REurogentecCCTTCGCAACTCACCACTGTFHV RNA1 69FEurogentecCCAGATCACCCGAACTGAATFHV RNA1 1002REurogentecCGACCGATGGAAACCAGCAGTTCFHV RNA2 70FEurogentecCGTCACAACAACCCAAACAGFHV RNA2 701REurogentecCCACCGCTAGAACACCATCTDCV 3133FEurogentecGTTGCCTTATCTGCTCTGDCV 4328REurogentecCGCATAACCATGCTCTTCTGDCV 4235FEurogentecCGACTCGTACTGGGGATTGTDCV 4863REurogentecAGGAAATCCTGGTGACGTTG**Software and Algorithms**RR Core Team<http://www.R-project.org/>Graphpad PrismGraphpad<https://www.graphpad.com/>FastQCFastQC<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>CutadaptCutadapt<https://cutadapt.readthedocs.io/en/stable/>**Other**Nanoject II injectorDrummond Scientific3-000-204

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to Maria-Carla Saleh (<carla.saleh@pasteur.fr>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Fly and mosquito stocks {#sec4.3.1}

The following fly stocks were used: *w*^*1118*^ (Bloomington), *Ago-2*^*414*^ ([@bib40]), *y*^*1*^ *hop*^*m38*^*/FM7c* (J.-L. Imler), *hop*^*mv1*^*/xˆx v*^*+*^ *yy*^*+*^ (J.-L. Imler), *w*^*1118*^ *; ; Df(3) E*^*20i*^ *rel* (J.-L. Imler), *y*^*d2*^ *w*^*1118*^*; P{ry*^*+t7.2*^ *= ey--FLP.N}2 ; Dcr-2*^*L811fX*^ (obtained from P. Zamore, ([@bib59])), *yw ; Dcr-2*^*G31R*^*, yw ; Dcr-2*^*G173E*^*, yw ; Dcr-2*^*C473Y*^*, yw ; Dcr-2*^*A500V*^ (4 strains obtained from J-L. Imler, described in [@bib27]), Vago control and *Vago*^*ΔM10*^ from J.-L. Imler ([@bib12]). Hopscotch homozygotes knock-out flies were obtained by crossing y^1^ hop^m38^/FM7c virgins and hop^mv1^/xˆx v^+^ yy^+^ males. All lines were tested for the presence of *Wolbachia*, and treated with 0.05 mg/ml tetracycline if necessary. All flies were regularly tested by RT-PCR for NoV, CrPV, DAV, DXV, DCV and FHV. Flies were reared on standard medium at 25°C, in tubes containing around 50 flies. All experiments were performed with 4-6-day-old female flies, to be consistent with other studies ([@bib16], [@bib48]). Experiments were performed 3 independent times. Flies or mosquitoes were always analyzed individually except for small RNAs deep-sequencing. Titration experiments featured 10 individual flies - each plotted by a single dot - per time point (except at t = 0 hr post-infection, n = 3 flies) and were analyzed with ANOVA (excluding t = 0 time point, α = 0.05). Survival experiments were done with 3 replicates in individual tubes, each tube containing 25 flies (75 flies total, [Figure 1](#fig1){ref-type="fig"}) or 20 flies (60 flies total, [Figures 7](#fig7){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}). Log-rank (Mantel-Cox) test was performed. Other experiments were tested using two-tailed Mann-Withney test, a non-parametric test, with a threshold at 0.05. Mean and standard error from the mean (SEM) are indicated in the graphs.

*Aedes aegypti* female mosquitoes belonged to the 7^th^ generation of a colony derived from wild *Aedes aegypti* collected in Kamphaeng Phet Province, Thailand. Mosquitoes were grown at 28°C and fed with 10% sucrose. A day prior blood feeding, females were selected and starved for a day. For each experiment, 30 individual mosquitoes were titrated per condition. Initial experiment ([Figure 5](#fig5){ref-type="fig"}F) was repeated 3 independent times and AZT rescue experiment was repeated two independent times ([Figure 5](#fig5){ref-type="fig"}G). Results were analyzed using a Fisher's exact test, with α = 0.05.

### Viruses and Cells {#sec4.3.2}

*Drosophila* S2 cells (Invitrogen) were cultured in Schneider's *Drosophila* medium supplemented with 1% Penicillin-Streptomycin (P-S, Sigma) and 10% fetal calf serum, at 25°C. BHK-21 cells and Vero cells were maintained in Dulbelcco's modified Eagle's medium (DMEM, GIBCO) supplemented with 10% newborn calf serum (NCS, GIBCO) and 1% P-S at 37°C with 5% CO~2~.

Sindbis was produced from the pTR339 infectious clone and CHIKV from the 06-049 infectious clone. Sindbis replicon was produced from the pSINrep5 clone ([@bib5]). Viral RNA was *in vitro* transcribed using the mMessage mMachine SP6 kit (Thermo Fisher Scientific) and 10 μg RNA was electroporated in BHK-21 cells in an XCell Gene Pulser Biorad. These electroporations were used to infect BHK-21 cells to give a stock of virus that was titered by plaque assay on Vero cells. Briefly, 24-well plates were seeded with 2 × 10^5^ Vero cells and infected with 10-fold dilutions of each sample, before being overlaid with DMEM containing 2% NCS and 0.8% agarose. Cells were fixed with formaline at 48 hr post-infection for Sindbis and 72 hr for CHIKV and stained with crystal violet. Stock viruses were passaged at MOI 1 (low MOI) or at MOI 25 (high MOI) in BHK-21 cells, and titered by plaque assay. Stocks of Sindbis-WT, Sindbis-highDG and Sindbis-equalDG were concentrated by ultracentrifugation on 20% sucrose cushion, 2 hr at 107,000 × *g* using a SW41 Ti rotor in an Optima XPN-100 centrifuge (Beckman Coulter). Point mutations of low fidelity variants were resequenced in stocks and in flies 7 days post-infection.

Sindbis replicon was produced by electroporating 5 μg of replicon RNA and 5 μg of helper RNA generated from pDH(26S) plasmid ([@bib5]) in BHK-21 cells. Supernatant was collected at 24 hr post-electroporation and concentrated by ultracentrifugation as previously described.

FHV and DCV stocks were prepared on low-passage S2 cells and titers were measured by end-point dilution. S2 cells (2.5 × 10^5^ cells per well in a 96-well plate) were inoculated with 10-fold dilution of virus stocks. At 7 and 14 dpi, the cytopathic effect was analyzed. Titers were calculated as TCID~50~/mL according to a published method ([@bib46]).

### Human Blood and Ethics Statement {#sec4.3.3}

Human blood used in this study was obtained through the ICAReB biobank (<https://research.pasteur.fr/en/team/biobanking-icareb/>) and manipulated under authorization number HS 2016-24321.

Method Details {#sec4.4}
--------------

### Isolation of Circular vDNA and Detection by PCR {#sec4.4.1}

Fruit flies were injected with 100 TCID~50~ of FHV or 80 TCID~50~ of DCV and collected at 7 days post-infection. Alternatively, fruit flies were injected with 400 PFU of Sindbis-WT or Sindbis-WT+D~G~ and collected at the indicated time point. *Aedes* mosquitoes were fed 10^5^ PFU of the indicated CHIKV stock and collected two weeks post-infection. Individual flies or mosquitoes were crushed in 100 μL of squishing buffer (10 mM Tris, pH 7.5, 60 mM NaCl, 10 mM EDTA, 200mg/μL proteinase K from Eurobiol) and the sample was incubated at 37°C for 1 hr. After phenol-chlorophorm purification, sample was treated for 30 minutes with 50 μg/μL RNase A, then DNA was phenol-chlorophormed again. Finally, 2 μg of resulting DNA was treated with Plasmid-Safe ATP-dependent DNase (Epicenter) for 16 hr at 37°C. ATP and enzyme were added again and the sample was incubated at 37°C for 24 hr. This last step was repeated one time with addition of ATP and enzyme. Enzyme was heat-inactivated 15 minutes at 70°C, before PCR on Rp49 served as a positive control for digestion of linear DNA.

PCR were performed using Phusion polymerase (Thermo Scientitic) according to the manufacturers instruction, using primers 414F and 913R for Sindbis DNA. Primers sequences can be found in the [Key Resources Table](#sec4.1){ref-type="sec"} or in [Table S3](#mmc1){ref-type="supplementary-material"}, related to [Figure 1](#fig1){ref-type="fig"}. FHV RNA1 DNA was detected with 69F and 1002R, FHV RNA2 with 70F and 701R, DCV vDNA with 3133F and 4328R or with 4235F and 4863R. Fly linear DNA was detected by targeting Rp49 using primer 144F and 465R. Mitochondrial fly DNA was detected using 794F and 1137R. To detect Sindbis D~G~ vDNA, primers 1644F and 11041R were used; 1644F and 10656R for D~G~ cvDNA. cvDNA detected after Sindbis-replicon injection was detected by nested PCR: a first PCR was performed using primers 91F and 1267R. 0.4 μL of the PCR product was amplified in a subsequent PCR using primers 414F and 913R.

### Fly Injection with cvDNA and Survival {#sec4.4.2}

S2 cells were infected with 1 MOI of FHV, or not infected, and collected 7 days post-infection. cvDNA was isolated as described in "Isolation of circular vDNA and detection by PCR." To verify the absence of viral RNA, cvDNA stock was reverse transcribed using the Maxima H Minus First Strand cDNA synthesis kit (Thermofisher Scientific) and assessed by PCR.

For immunization, 4-5 days old flies were injected intrathoracically with 10 ng of cvDNA isolated from FHV-infected or non-infected S2 cells. 48 hr later, flies were challenged with 80 TCID~50~ of FHV, 100 TCID~50~ of DCV or control injection (Tris), in 50 nL using a Nanoject II injector (Drummond Scientific). Survival was monitored daily.

### Deep-sequencing of Circular vDNA {#sec4.4.3}

For generation of FHV cvDNA libraries, S2 cells were infected with 1 MOI of FHV, or not infected, and collected 7 days post-infection. Samples were phenol-chlorophorm purified and processed as described ([@bib24]). Briefly, after cvDNA purification using Plasmide-Safe DNase, samples were ethanol-precipitated and amplified by random RCA (Illustra TempliPhi kit, GE Healthcare). DNA concentration was measured with DNA PicoGreen reagent (Invitrogen) and samples were diluted to 0.2 ng/μl. One ng of DNA was used to prepare libraries with the Nextera XT library kit (Illumina). A PCR of 12 cycles was performed with index primers to amplify libraries, before DNA analysis on a high sensitivity DNA Bioanalyzer chip (Agilent Technologies). 2 × 250 nucleotides paired-end sequencing was performed on a MiSeq sequencer (Illumina). Reads were analyzed with in-house Perl scripts

### Fly Injection with cvDNA and Deep-sequencing of siRNAs {#sec4.4.4}

FHV cvDNA was obtained as described in "Isolation of circular vDNA and detection by PCR ". 4-5 days old flies were injected with 10 ng of FHV cvDNA and collected 3 days post-injection. RNA from 15 flies was extracted using TRIzol reagent (Thermo Fisher Scientific) and processed for next-generation sequencing of small RNAs.

### cvDNA Cloning {#sec4.4.5}

The overall strategy to clone unintegrated cvDNAs was to linearize isolated cvDNA by digestion with a single-cutter restriction endonuclease and insertion of the linearized cvDNA into a similarly restricted low-copy plasmid vector, pgL338-30, which is commonly used for cloning lentivirus sequences ([@bib11]). Restriction endonucleases were chosen based in part on FHV-retrotransponson chimeras identified in [@bib16]. cvDNA was isolated as described above, and digested with either *Sph*1 or *Mlu*1, which cut FHV RNA1 at nt 1036 and 1224, respectively. Following digestion, DNA was isolated and amplified with FHV RNA 1-specific primers containing the *Sph*1 or *Mlu*1 restriction site ([Table S2](#mmc1){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}). Amplified DNA was isolated, digested with *Sph*1 or *Mlu*1, and ligated to similarly restricted pLg338-30 plasmid DNA. Ligated DNA was used to transform MAX Efficiency Stbl2 Competent Cells (Invitrogen) using procedures recommended by the manufacturer. Colonies were screened by PCR using FHV RNA 1-specific primers and positive colonies were Sanger sequenced using primers specific for FHV RNA 1, pLG338-30 and *Drosophila* retrotransposons ([Table S1](#mmc1){ref-type="supplementary-material"}, related to [Figure 4](#fig4){ref-type="fig"}). Sequences were assembled and analyzed using MacVector.

### Production of the Sindbis-WT+D~G~ and Control Stocks {#sec4.4.6}

To produce Sindbis-WT+D~G~ stock, BHK-21 cells were electroporated with 5 μg of Sindbis-WT RNA and 5 μg of D~G~ RNA in an XCell Gene Pulser Biorad. After 48h, supernatant was collected and concentrated by ultracentrifugation as described.

To produce the Sindbis-WT control stock, a "fake" *in vitro* transcription of D~G~ RNA was performed, where all the reagents were present except the SP6 enzyme. BHK-21 cells were electroporated with 5 μg of Sindbis-WT RNA and the equivalent in volume of "fake" *in vitro* transcription. In this way, putative traces of D~G~ plasmid used to produce D~G~ RNA by *in vitro* trancription were present both in the Sindbis-WT and the Sindbis-WT+D~G~ stock.

### Injection and Titration of Sindbis-Infected Flies {#sec4.4.7}

Four to six-days old female flies were intrathoracically injected with 50 nL containing 400 PFU of Sindbis-WT, Sindbis-highDG or Sindbis-equalDG diluted in 10 mM Tris-HCl (pH 7.5). Sindbis-infected flies were frozen at the appropriate time point, crushed in 55 μL of PBS using a Pellet Pestle (Sigma-Aldrich), centrifuged at 10 000 x *g* for 5 min and titrated by plaque assay on Vero cells.

### Survival of Sindbis-Infected Flies {#sec4.4.8}

Four to six-days old female flies were intrathoracically injected with 50 nL containing 400 PFU of Sindbis-WT, Sindbis-highDG or Sindbis-equalDG diluted in 10 mM Tris-HCl (pH 7.5), or mock-infected with Tris. Survival was monitored daily, and flies were placed on fresh medium every two to three days.

### Mosquitoes Rearing, Feeding and Titration {#sec4.4.9}

The insectary conditions for mosquito maintenance were 28°C, 70% relative humidity and a 12 h light: 12 h dark cycle. Adults were maintained with permanent access to 10% sucrose solution.

6-8 days old female mosquitoes were fed with 10^5^ PFU of CHIKV diluted in prewashed human blood (iCareB platform, Institut Pasteur). Mosquitoes were offered the infectious or control blood meal for 30 min through a membrane feeding system (Hemotek Ltd) set at 37°C with a piece of desalted pig intestine as the membrane. Following the blood meal, fully engorged females were selected and incubated at 28°C, 70% relative humidity and under a 12 h light: 12 h dark cycle with permanent access to 10% sucrose.

Individual mosquitoes were crushed in 70 μL of PBS with a Pellet Pestle (Sigma-Aldrich) and titered by plaque assay on Vero cells. The technique allowed us to detect titers superior to 100 pfu.

### AZT Treatment {#sec4.4.10}

Wild-type flies were fed daily with 93 mM AZT (Sigma-Aldrich) in 25% sucrose for a week or fed only with sucrose. After a week, flies were infected with 400 PFU of Sindbis or Tris-HCl 10 mM, pH 7.5 (as a control), in 50 nL using a Nanoject II injector (Drummond Scientific).

After infection, flies were kept with a 25% sucrose solution supplemented or not with 93 mM AZT during 3 days. Mosquitoes were fed with a solution of 10% sucrose supplemented with 5 mM AZT a week prior infection and fed with a blood meal as previously described.

### Sindbis vDNA Detection by qPCR {#sec4.4.11}

vDNA detection by qPCR was performed by injecting 4 to 6-day-old female with 10 000 PFU of Sindbis virus and by freezing the flies at the indicated time point. vDNA was extracted from flies as previously described. qPCR was performed using Power SYBR Master Mix (Applied Biosystems) according to the manufacturer's instruction, and run on a StepOne Plus real-time PCR system machine (Applied Biosystems). Primers 1215F and 1267R were used for Sindbis DNA and primers 144F and 465R were used for Rp49 ([Table S3](#mmc1){ref-type="supplementary-material"}, related to [Figures 5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}).

### Plot of Relative vDNA Production Over Relative Viral Load ([Figure 6](#fig6){ref-type="fig"}B) {#sec4.4.12}

#### Relative vDNA Production (y Axis) {#sec4.4.12.1}

Wild-type flies, or the indicated Dcr-2 mutant, where infected with 10 000 PFU of Sindbis-WT or Sindbis-highDG, and vDNA accumulation was measured by qPCR at 7 hr post-infection. Relative vDNA production is calculated by dividing the vDNA production of each fly strain by the value obtained for wild-type flies (mean of 3 independent experiments).

#### Relative Viral Load (x Axis) {#sec4.4.12.2}

Wild-type or Dcr-2 mutant flies were infected with 400 PFU of Sindbis-WT or Sindbis-highDG, and titers were measured by plaque assay at 3, 5 and 7 days post-infection (n = 10 flies per condition). The percentage of Sindbis-highDG titer relative to Sindbis-WT titer was calculated for these time points. This value was averaged on 3 independent experiments. The final value was obtained by calculating the ratio over the value obtained for wild-type flies.

### RNase and DNase Treatments {#sec4.4.13}

DNA extracted from individual flies was digested with 10 μg/mL of RNase A/T1 (Thermo Fisher Scientific) 1 hr at 37°C, then phenol-chlorophorm-purified. Alternatively, DNA was digested using the Turbo DNA-free kit (Life technologies) according to the manufacturers' instructions. vDNA was measured by qPCR.

### DVGseq Pipeline {#sec4.4.14}

Individual flies were crushed in 1 mL of TRIzol reagent (Invitrogen) using a Pellet Pestle (Sigma-Aldrich) and RNA was extracted following the manufacturer's instructions. cDNA was produced using 100 ng of RNA using the Maxima H Minus First Strand cDNA synthesis kit (Thermo Fisher Scientific) according to the manufacturer's instructions. cDNA was further amplified by PCR using Phusion polymerase using the primers 414F and 11634R for Sindbis ([Table S3](#mmc1){ref-type="supplementary-material"}, related to [Figure S2](#mmc1){ref-type="supplementary-material"}). PCR products were purified on NucleoSpin Gel and PCR Clean-up column (Macherey-Nagel). For every analysis, RNA was extracted in bulk. Reverse-transcription, as well as PCRs, were performed in the same 96-well plate. For controls, *in vitro* transcribed RNA of the virus of interest was included, mixed or not with different amount *in vitro* transcribed RNAs of known DVG. Because every step of the pipeline is performed in bulk, DVG detected in samples that are artifacts (for example artifacts of PCR) can be removed because they will be present in the controls. PCR products were fragmented (Fragmentase, Thermo Fisher Scientific) before their linkage to Illumina multiplex adapters, their clusterization and sequencing (Illumina cBot and GAIIX technology). CASAVA software was used to demultiplex the sequences. The sequenced reads for each sample were aligned to their respective reference genomes using BWA MEM. Samples with \< 100,000 aligned reads were excluded from further analysis. DVG reads were identified as chimeric reads (identified with SA tags) consisting of two linear alignments covering the whole read. The end position of the leftmost alignment and the start position of the rightmost alignment were referred to as "cut start position" and "cut end position," respectively. DVG were defined as a set of \> 100 DVG reads with the same cut start and end positions. DVG with cut start position \< 600 were found in control samples containing only full-length viral RNA; we consequently concluded they were due to PCR artifacts and removed them from further analyses in all samples. The raw frequency of a DVG was computed from the drop in number of reads before and after the cut start or end position (chosen so as to increase power):$$f_{r} = \frac{N_{i} - N_{i + 1}}{N_{i}}\ \text{if}\ N_{i} > N_{j};\quad f_{r} = \frac{N_{j} - N_{j - 1}}{N_{j}}\ \text{otherwise,}$$where *f*~*r*~ denotes the raw frequency, *N*~*k*~ the total number of reads at position *k*, *i* the cut start position, *j* the cut end position and *L* the genome length. Because of PCR biases toward amplifying DVG rather than full-length genomes, raw frequencies were overestimating DVG frequencies, and we used control samples containing mixes of full-length and D~G~ RNA at different ratios to normalize these frequencies in each individual plate. Raw frequencies were linked to actual frequencies by the following equation:$$\log\left( \frac{f_{a}}{1 - f_{a}} \right) = \alpha\ \log\left( \frac{f_{r}}{1 - f_{r}} \right) + \beta,$$where *f*~*r*~ denotes raw frequencies and *f*~*a*~ denotes actual frequencies; α and β are fixed parameters. One such linear regression was fitted per plate, using the control samples (all adjusted *R*^2^ were \> 0.98), and was used to normalize raw frequencies of DVG.

### Deep-sequencing of Small RNAs {#sec4.4.15}

WT, *Dcr-2*^G31R^, *Dcr-2*^A500V^ or *Dcr-2*^L811fX^ were injected with 400 pfu of Sindbis-WT and collected at 7 days post-infection; RNA was extracted from 15 flies using TRIzol and processed for small RNAs sequencing. 19-29 nt RNAs were purified from a 15% acrylamide/bisacrylamide (37.5:1), 7 M urea gel and used for library preparation using NEBNext Multiplex Small RNA Library Prep (Illumina, New England Biolabs). The 3′ adaptor from Integrated DNA Technologies (linker 1) and in-house-designed indexed primers were used in the process. Sequencing of librairies diluted to 4 nM was performed on a NextSeq 500 sequencer (Illumina) with a NextSeq 500 High-Output Kit v2 (Illumina) (75 cycles). Reads were analyzed with in-house Perl scripts. Graphs were generated with FastQC ([www.bioinformatics.babraham.ac.uk/projects/fastqc/](http://www.bioinformatics.babraham.ac.uk/projects/fastqc/){#intref0040}) to assess the quality of fastq files. Adaptors and low-quality bases were trimmed from reads using cutadapt (<https://cutadapt.readthedocs.io/en/stable/>) and reads with low quality were eliminated. Reads were mapped on genomes using bowtie1 ([@bib25]) to generate sam files, allowing one mismatch between a read and its target. Sam files were processed to produced bam indexed files using samtools package ([@bib30]). Graphs were generated from bam files using in-house R scripts and the Bioconductor Rsamtools and Shortreads libraires ([@bib38]).

### Construction of Dcr-2 helicase Expression Plasmid {#sec4.4.16}

The helicase domain of Dcr-2 was cloned as a V5/3XFLAG tagged fusion protein into pAc 5.1 V5 His(A) (Invitrogen) using the restriction free cloning method. The 3XFLAG region from p3XFLAG-CMV-9 Expression Vector (Sigma-Aldrich) was amplified by PCR using primers Flag_F and Flag_R ([Table S3](#mmc1){ref-type="supplementary-material"}, related to [Figure 6](#fig6){ref-type="fig"}). This PCR product was used as a primer for a second PCR using pAc 5.1 V5 His(A) as template. During this amplification step, the His tag was removed from the original plasmid. To clone the helicase of *Drosophila melanogaster* Dcr-2 in pAc 5.1 V5 3XFLAG, Dcr-2 helicase was amplified by PCR from cDNA from wild-type flies (*w*^*1118*^) with primers Dicer-2_Flag_F and Dicer-2_Flag_R ([Table S3](#mmc1){ref-type="supplementary-material"}, related to [Figure 6](#fig6){ref-type="fig"}). The purified PCR product was used as primer for a PCR using pAc 5.1 V5 3XFLAG as a template. The resulting plasmid, designated *pAc5.1 Dcr-2 helicase V5 3XFLAG*, carries the coding region of Dcr-2 helicase downstream of the *Drosophila* actin promoter and two tags for protein purification in the C-terminal region, V5 and 3XFLAG. Final plasmid was sequenced to verify the presence of inserts at the desired positions without mutations, deletions or insertions.

### Immunoprecipitation Assays {#sec4.4.17}

S2 cells were seeded at 1x 10^6^ cells in 6 wells plate and transfected with 400 ng/well of *pAc5.1 Dcr-2 helicase V5 3XFLAG* using Effectene Transfection Reagent (QIAGEN) following manufacturer's indications. Controls included empty vector *pAc5.1 V5 3XFLAG* and *pAc5.1 CG4572 V5 3XFLAG.* The next day, cells were extensively washed and infected with Sindbis highDG or Sindbis wt (MOI = 2,5). At 72 h post-infection, cells were collected and 10% was kept for RNA extraction with TRIzol (designated input RNA). The remaining cells were homogenized in 100 uL of cold lysis buffer containing 50 mM Tris pH 7.5, 150 mM NaCl, 2.5 mM MgCl2, 250mM sucrose, 0.05% NP-40, 0.5% Triton X-100, 10% glycerol, 1mM DTT, 1mM EDTA, 1X protease inhibitor cocktail (Roche), 5uL/mL RNase OUT (Thermo Fisher Scientific) and incubated for 30 minutes at 4°C with rocking agitation. Cell lysates were clarified by centrifugation at 12,000 rpm for 15 minutes (4°C), and protein concentration in the supernatant was determined using the Bicinchoninic Acid Assay (Pierce). For immunoprecipitation, 100 mg of total lysate were incubated in a final volume of 1 mL lysis buffer with either 9 ug pre-equilibrated ANTI-FLAG M2 Magnetic Beads (Sigma) or Gammabind Plus Sepharose (GE Healthcare) coupled with 10 ug V5 monoclonal antibody (Invitrogen). Reactions were incubated using a roller shaker for 4 h at 4°C, washed 3X in TBS buffer (50 mM Tris pH 7.5, 150 mM NaCl) supplemented with 250mM sucrose and 0.5mM DTT followed by a final wash in TBS supplemented with 250mM sucrose and 0.5mM DTT and RNase OUT. Samples were eluted either with 3X Flag Peptide (Sigma) or lysis buffer without protease inhibitors at high stringency conditions (800mM NaCl) with proteinase K treatment. Eluates were then further subjected to RNA isolation (TRIzol) and RT-PCR for detection of Sindbis virus RNA.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

The (non-parametric) log-rank test was used to compare survival curves ([Figures 1](#fig1){ref-type="fig"}F, 1G, [7](#fig7){ref-type="fig"}B, 7D, and [S5](#mmc1){ref-type="supplementary-material"}B--S5D). Two-way ANOVA was performed to compare viral titers of two viruses over time ([Figures 5](#fig5){ref-type="fig"}C, 5D, [S2](#mmc1){ref-type="supplementary-material"}C--S2F, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B) following log-transformation; homoscedasticity and normality of the distributions were satisfactory, and treatment (virus) effect was reported. To compare two distributions, the non-parametric Mann--Whitney test was used ([Figures 5](#fig5){ref-type="fig"}E, [7](#fig7){ref-type="fig"}A, 7C, [S2](#mmc1){ref-type="supplementary-material"}B, [S3](#mmc1){ref-type="supplementary-material"}A, S3C, and [S5](#mmc1){ref-type="supplementary-material"}A). To compare mosquito outcome (infected or not) between different viruses, we performed χ^2^ tests of independence on 2 × 2 contingency tables ([Figures 5](#fig5){ref-type="fig"}F and 5G). All statistical tests were performed on Graphpad Prism version 5 (<https://www.graphpad.com/>). *P*-values \< 0.05 were considered significant.

Data and Software Availability {#sec4.6}
------------------------------

The accession numbers for the RNA, DNA, and small RNA sequences reported in this paper are SRA NCBI: PRJNA387403, PRJNA387406, PRJNA416764, and PRJNA416718.
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